# Fresenius Medical (FMS) — Earnings

FMS · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/fms/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.65 |
| EPS estimate | $0.63 |
| EPS surprise | +2.62% |
| Revenue surprise | +2.02% |
| Revenue | $5.6B |
| Revenue estimate | $5.5B |
| Reported | Aug 3, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1333141/000110465926089725/tm2622055d2_6k.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/1e28f0db-2104-415e-1fc2-c34797f28977.html) |

Fresenius Medical Care reported Q2 2026 results on August 3, 2026. Earnings per share were $0.65, ahead of the $0.63 estimate by 2.62%. Revenue was $5.6 billion, 2.02% above the $5.5 billion estimate. Compared with Q2 2025, EPS rose about 23% from $0.53, and revenue edged up from $5.5 billion.

Revenue has been broadly stable, between $4.8 billion and $6.0 billion a quarter across the table, while earnings have grown. Annual EPS was $1.61 in 2022 and dipped to $1.39 in 2023, then rose to $1.67 in 2024 and $2.49 in 2025, up about 49%. The first half of 2026 totals $1.18, about 17% above the first half of 2025. Q4 2025 set the highs in the table at $0.85 per share and $6.0 billion in revenue. The EPS low is $0.29, from Q1 2023. Over the last 20 quarters, the company beat the EPS estimate 17 times. The most recent miss was Q1 2026, at 3.15% below.

Fresenius Medical Care reported Q3 results between October 31 and November 5 in each of the past five years. That points to early November 2026 for the next report. It will show whether EPS keeps running above year-earlier levels.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 3, 2026 | $0.63 | $0.65 | 2.62% | $5.5B | $5.6B |
| Q1 2026 | May 5, 2026 | $0.55 | $0.53 | -3.15% | $5.4B | $5.4B |
| Q4 2025 | Feb 24, 2026 | $0.67 | $0.85 | 26.81% | $5.7B | $6.0B |
| Q3 2025 | Nov 4, 2025 | $0.59 | $0.63 | 6.34% | $5.7B | $5.6B |
| Q2 2025 | Aug 5, 2025 | $0.51 | $0.53 | 4.05% | $5.7B | $5.5B |
| Q1 2025 | May 6, 2025 | $0.43 | $0.48 | 11.88% | $5.3B | $5.5B |
| Q4 2024 | Feb 25, 2025 | $0.42 | $0.48 | 12.90% | $4.9B | $5.3B |
| Q3 2024 | Nov 5, 2024 | $0.38 | $0.45 | 18.29% | $5.4B | $5.3B |
| Q2 2024 | Jul 30, 2024 | $0.37 | $0.38 | 2.00% | $5.4B | $5.1B |
| Q1 2024 | May 7, 2024 | $0.28 | $0.36 | 27.06% | $4.9B | $5.1B |
| Q4 2023 | Feb 20, 2024 | $0.44 | $0.48 | 8.92% | $5.4B | $5.4B |
| Q3 2023 | Nov 2, 2023 | $0.29 | $0.30 | 5.22% | $5.2B | $5.2B |
| Q2 2023 | Aug 2, 2023 | $0.29 | $0.32 | 11.72% | $5.3B | $5.3B |
| Q1 2023 | May 9, 2023 | $0.24 | $0.29 | 19.92% | $5.1B | $5.2B |
| Q4 2022 | Feb 21, 2023 | $0.31 | $0.46 | 49.04% | $5.3B | $5.3B |
| Q3 2022 | Oct 31, 2022 | $0.35 | $0.40 | 15.41% | $4.9B | $5.3B |
| Q2 2022 | Aug 2, 2022 | $0.40 | $0.39 | -2.29% | $4.8B | $4.9B |
| Q1 2022 | May 4, 2022 | $0.36 | $0.36 | 0.56% | $4.8B | $4.8B |
| Q4 2021 | Feb 22, 2022 | $0.50 | $0.51 | 2.06% | $5.2B | $5.3B |
| Q3 2021 | Nov 2, 2021 | $0.55 | $0.54 | -1.45% | $5.3B | $5.1B |

## Frequently Asked Questions

### When did Fresenius Medical (FMS) last report earnings?

Fresenius Medical last reported on Aug 3, 2026, covering fiscal Q2 2026.

### Did FMS beat earnings estimates?

Yes. Fresenius Medical reported EPS of $0.65 for Q2 2026 against a $0.63 estimate — a 2.62% beat.

### How much revenue did FMS report last quarter?

Fresenius Medical reported $5.6B in revenue for Q2 2026, against a consensus estimate of $5.5B.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).